CD47 activation by TSP-1 is emerging as a critical signaling axis in driving tumor behavior, as it is indeed involved in the regulation of tumor cell viability, differentiation of cancer stem cells, tumor angiogenesis and vessel perfusion, and resistance to chemo- and radiotherapy [1,7,8], as well as inhibition of anti-tumor immune response. This evidence concerns the gene CD47 and cancer.